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Summary
Background: We report on the study design and protocol of a 
randomised controlled trial (Acupuncture in Seasonal Allergic 
Rhinitis, ACUSAR) that investigates the efficacy of acupuncture 
in the treatment of seasonal allergic rhinitis (SAR). Objective: 
To investigate whether acupuncture is non-inferior or superior 
to (a) penetrating sham acupuncture and (b) rescue medication 
in the treatment of SAR. Design: 3-armed, randomised control-
led multi-centre trial with a total follow-up time of 16 weeks in 
the 1st year and 8 weeks in the 2nd year. Setting: 41 physicians 
in 37 out-patient units in Germany specialised in acupuncture 
treatment. Patients: 400 seasonal allergic rhinitis patients with 
clinical symptoms and test-positive (skin-prick test and/or spe-
cific IgE) to both birch and grass pollen. Interventions: Patients 
will be randomised in a 2:1:1 ratio to one of three groups: (a) 
semi-standardised acupuncture plus rescue medication (ceti-
rizine); (b) penetrating sham acupuncture at non-acupuncture 
points plus rescue medication; or (c) rescue medication alone 
for 8 weeks (standard treatment group). Acupuncture and sham 
acupuncture will consist of 12 treatments per patient over 8 
weeks. Main Outcome Measures: Average means of the Rhini-
tis Quality of Life Questionnaire (RQLQ) overall score and the 
Rescue Medication Score (RMS) between weeks 6 and 8 in the 
first year, adjusted for baseline values. Outlook: The results of 
this trial available in 2011 will have a major impact on the deci-
sion of whether acupuncture should be considered as a thera-
peutic option in the treatment of SAR.
Schlüsselwörter 
Akupunktur · Traditionelle chinesische Medizin ·  
Komplementärmedizin · Allergie · Saisonale  
allergische Rhinitis · Randomisierte klinische Studie 
Zusammenfassung
Hintergrund: Wir berichten über das Studiendesign und essen-
zielle Teile des Protokolls einer randomisierten Studie (Acu-
puncture in Seasonal Allergic Rhinitis, ACUSAR) bei Patienten 
mit saisonaler allergischer Rhinitis. Ziel: Ziel der Studie ist es, 
zu untersuchen, ob Akupunktur in der Therapie von saisonaler 
allergischer Rhinitis nicht unterlegen bzw. wirksamer ist als (a) 
penetrierende Sham-Akupunktur bzw. (b) Bedarfsmedikation 
allein. Design: Dreiarmige kontrollierte klinische Multicenter-
Studie mit einem Follow-up von 16 Wochen im 1. und 8 Wo-
chen im 2. Jahr. Prüfzentren: 41 auf Akupunktur spezialisierte 
Ärzte in 39 Praxen und Ambulanzen in Deutschland. Patienten: 
400 Patienten mit klinisch manifester und positiv getesteter 
(Prick-Test und/oder spezifisches IgE) saisonaler allergischer 
Rhinitis auf Birken- und Gräserpollen. Studienintervention: Pa-
tienten erhalten nach einer 2:1:1-Verteilung randomisiert en-
tweder (a) eine semi-standardisierte Akupunkturbehandlung 
mit Bedarfsmedikation (Cetirizin), (b) eine penetrierende Sham-
Akupunktur an Nicht-Akupunktur-Punkten mit Bedarfsmedika-
tion oder (c) Bedarfsmedikation alleine für 8 Wochen. Die Aku-
punktur-Intervention erfolgt in 12 Akupunktursitzungen über 
einen Zeitraum von 8 Wochen. Hauptzielkriterien: Jeweils die 
Score-Mittelwerte des «Rhinitis Quality of Life Questionnaire» 
(RQLQ) und der Bedarfsmedikation gemessen mit dem «Rescue 
Medication Score» (RMS) zwischen Woche 6 und 8, adjustiert 
für die Baseline-Werte. Ausblick: Die Studienergebnisse sind 
2011 zu erwarten und werden die Basis für eine wissenschaftli-
che Neubeurteilung der Akupunktur bei saisonaler allergischer 
Rhinitis bieten.
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Authors of two recently published systematic reviews draw 
the conclusion that there is currently insufficient evidence to 
support or refuse the use of acupuncture in patients with AR 
[13, 14]. They pointed out that previous studies on the efficacy 
of acupuncture in AR have suffered from a variety of metho-
dological limitations, such as small patient numbers or the 
lack of a sham-acupuncture control group and they stated, 
that a large well-conducted RCT, which overcomes identified 
methodological problems would be required.
Aim of the Study
The primary objective of the ACUSAR trial is to investigate 
whether an 8-week semi-standardised acupuncture plus res-
cue medication is non-inferior (1st step) or superior (2nd 
step) to (a) penetrating sham acupuncture intervention plus 
rescue medication and (b) rescue medication alone in the 
treatment of SAR. Secondary objectives include an assess-
ment of long-term effectiveness and use of rescue medication 
over a period of 8 weeks in the 2nd year and an evaluation of 
cost-effectiveness of acupuncture versus standard treatment.
Patients and Methods
Design
The ACUSAR study is a 3-armed, randomised, parallel controlled multi-
centre trial investigating the efficacy of acupuncture plus rescue medica-
tion versus penetrating sham acupuncture (involving superficial needling 
at non-acupuncture points) plus rescue medication in patients with SAR 
as well as the efficacy of acupuncture plus rescue medication versus res-
cue medication alone (fig. 2). Patients are blinded to treatment concern-
ing acupuncture and penetrating sham acupuncture in the study. After 
randomisation, patients in the acupuncture and penetrating sham acu-
puncture groups receive 12 treatment sessions over a period of 8 weeks. 
Introduction
Allergic rhinitis (AR) has become a major health problem. In 
the past 2 decades, there has been a marked increase in the 
prevalence of AR [1]. Direct yearly costs for AR in Europe 
are estimated at 1.0–1.5 billion Euros annually, whereas indi-
rect costs are estimated at 1.0–2.0 billion Euros [1]. A remark-
able number of patients are turning for relief to complemen-
tary and alternative medicine (CAM), such as acupuncture. 
The lifetime prevalence of CAM use in patients with AR 
ranges from 27–46%, and most of the patients who have not 
yet used CAM intend to do so in the future [2, 3]. In particu-
lar, acupuncture is used by 17–19% of AR patients [2, 3]. Be-
cause of this, acupuncture has increasingly become the focus 
of allergy specialists and scientists [4, 5]. In addition, acupunc-
ture was judged by specialists (48%) to be the CAM treat-
ment best supported by experimental evidence [4].
However, studies on the efficacy of acupuncture in patients 
with AR have yielded inconclusive results [6–12]. For exam-
ple, results of our pilot study indicate that the use of a combi-
nation of acupuncture and Chinese herbal medicine is supe-
rior to sham acupuncture and placebo treatment in patients 
with seasonal allergic rhinitis (SAR) [9]. Furthermore, results 
of a large pragmatic trial with >5,000 patients, published re-
cently, suggested that treating patients who suffer from AR 
with adjunctive acupuncture therapy leads to clinically rele-
vant benefits [12]. In addition, Xue et al. and Ng et al. [8, 11] 
demonstrated that acupuncture is effective in reducing subjec-
tive AR symptom scores while Magnusson et al. [10] found 
that acupuncture was not superior to sham acupuncture in re-
ducing clinical symptoms. The results of our prior trials [9, 12] 
provided the background and basis of the ACUSAR (Acu-
puncture in Seasonal Allergic Rhinitis) trial (fig. 1).
 
 
ACUSAR - Acupuncture for Seasonal Allergic Rhinitis - Version 011009 
10
 
Pragmatic RCT
Pilot RCT
Acupuncture in Routine Care AR (N = 5237)
Design: 3-armed partly randomised pragmatic clinical trial
Groups: Acupuncture vs. waiting list vs. non randomised acupuncture
Brinkhaus B et al. Ann Allergy Asthma Immunol 2008;101:535-543
Evaluation stage
ACUSAR Study (N = 400)
Design: 3-armed randomised controlled clinical trial
Groups: Acupuncture vs. penetrating sham acupuncture vs. standard treatment
Allergy Study (N = 52)
Design: 2-armed randomised controlled clinical trial
Groups: Acupuncture + CHM vs. penetrating sham acupuncture + Placebo CHM
Brinkhaus B et al. Allergy 2004;59:953-960
Classical RCT
Study
 
((Figure 1)) 
Fig. 1. ACUSAR study and previously con-
ducted studies on the effectiveness of acupunc-
ture in patients with AR. CHM = Chinese 
herbal medicine; RCT = randomised controlled 
clinical trial.
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taneous participation in other clinical trials; serious acute or chronic or-
ganic disease or mental disorder; pregnancy or breast feeding; current 
allergy desensitisation therapy, or during the past 2 years, or planned in 
the next 2 years. Further exclusion criteria include blood coagulation dis-
order and/or current use of anticoagulants; previous acupuncture treat-
ment for SAR; any CAM treatment at the moment, in the last 3 months, 
or planned within the 2 trial years.
Participating Physicians
Participating trial physicians were recruited from a network of approxi-
mately 100 practices; this network was established during our previous 
randomised acupuncture trials [15–18]. Physicians were required to fulfill 
all of the following criteria: (1) acupuncture training at least equivalent 
to an ‘A-diploma’ from one of the major German acupuncture societies 
(140 h of acupuncture training); (2) ≥3 years of practical experience with 
acupuncture; (3) participation in study training sessions on the trial meth-
ods, the interventions tested, and standards for performing clinical trials 
(ICH-GCP); (4) 50% of trial physicians had to have at least a ‘B-diploma’ 
(350 h); (5) 50% had to have experience working in clinical studies. 41 
practitioners in 37 out-patient units in Germany are currently participat-
ing in the studies. Non-medical acupuncturists were not included in the 
study.
Study Intervention and Informed Consent
The treatment strategies for acupuncture and penetrating sham acupunc-
ture were developed in a consensus process with experienced acupunc-
ture experts (see Acknowledgement) from two major German societies 
for medical acupuncture: the German Medical Acupuncture Association 
(Deutsche Ärztegesellschaft für Akupunktur; DÄGfA), Munich, and the 
International Society for Chinese Medicine, Munich (Societas Medicinae 
Sinensis, SMS). The acupuncture and the penetrating sham acupuncture 
were developed using the Delphi method with three rounds (two meet-
ings and one writing round) including acupuncture experts from two 
major acupuncture societies and experts on trial methodology. The final 
strategies were generally considered as a pragmatic compromise between 
the need for standardization and for individualization. 
Patient randomisation and the study intervention start at the begin-
ning of the birch pollen season. Both the acupuncture and the penetrating 
sham acupuncture treatments consist of 12 sessions of ≥20 and ≤40 min 
duration each, administered over a period of 8 weeks (preferably 2 ses-
In the rescue medication group, all patients receive rescue medication 
only for the first 8 weeks. During the following 8 weeks, they receive 12 
acupuncture treatments in the same way as in the group treated with a 
semi-standardised acupuncture regimen. The total follow-up study period 
per patient is 16 weeks in the 1st year and 8 weeks in the 2nd year.
This study is conducted according to common guidelines for clinical 
trials (Declaration of Helsinki, Version von Somerset West 1996), includ-
ing certification by an external in-house audit according to ICH-GCP at 
the Institute for Social Medicine, Epidemiology, and Health Economics, 
Charité University Medical Center Berlin, Germany, after recruitment of 
50–80% of the target sample size. The study protocol has been approved 
by the ethics review of the Charité University Hospital Berlin. 
For concealment of the allocation of the next patient, individual pa-
tient randomisation (2:1:1) into the 3 study arms is performed centrally by 
the external clinical trial unit (Koordinationszentrum Klinische Studien, 
KKS) at the Charité University Hospital Berlin. Patients who meet the 
inclusion criteria and give written and oral consent are included in the 
study. After a patient is included in the study, his or her physician phones 
the KKS, where the patient will be registered. Subsequently, the physi-
cian receives information from the KKS regarding patient allocation both 
by phone and fax. 
Patients
The ACUSAR trial aims to recruit a total of 400 patients. Recruitment 
for the trials started in April 2008. For inclusion in the ACUSAR study, 
patients must meet the following criteria: female or male patients (aged 
16–45 years) with SAR, clinically and test-positive (skin-prick test and/or 
specific IgE – at least class 2 of the radio-allergo-sorbent test (RAST), 
results to grass and birch pollen; patients with >2 years of moderate to 
severe SAR; visual analogue scale >40 and <80 mm for SAR symptoms 
during the past year; patients must be able to complete a diary for self-
evaluation of symptoms and recording use of anti-symptomatic medica-
tion; use of, or indication for, oral antihistamines as antiallergic medica-
tion, and written informed consent.
Main exclusion criteria for patients are one or more of the following 
diseases or conditions: perennial SAR or other types of chronic rhinitis; 
allergic asthma and/or moderate to severe atopic dermatitis; auto-im-
mune disorders; severe chronic inflammatory diseases; history of anaphy-
lactic reactions; hypersensitivity to rescue medication (cetirizine) or re-
lated drugs used in the study; specific immunotherapy for >3 years; simul-
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RQLQ x x      x                 x                x x  x     
RMS     
VAS       x   x   x   x  x   x   x   x   x                x                x   x   x x   x   x
SF-36 x    x                   x                x x
Costs
0
Sham Acupuncture
(n = 100).
Rescue Medication
(n = 100)
Randomisation
2 : 1 : 1
Follow-up
Acupuncture
(n = 200)
16
Follow-up
Year 1 Year 2
8
Acupuncture
Patients
Follow-up
0 8
Follow-up
Follow-up
Primary endpoint  
((Figure 2)) 
Fig. 2. Trial design, time schedule, and out-
come parameters of the ACUSAR study.). 
Outcome measures: RQLQ = Rhinitis Quality 
of Life Questionnaire; RMS = amount of anti-
allergic medication assessed daily by the Rescue 
Medication Score; VAS = visual analogue scale 
of SAR symptoms; SF-36 = German version of 
the health-related quality of life questionnaire.
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ticipating trial physicians are required to choose ≥5 points for penetrating 
sham acupuncture treatment out of a selection of 7 penetrating sham acu-
puncture points at non-classical sites which have to be needled bilaterally 
(≥10 needles altogether) in each session (table 2). Superficial insertion 
only using fine needles (≤20 mm long) is recommended. Needling sensa-
tion ‘de qi’ and manual stimulation of the needles should be avoided; the 
needles should be placed subcutaneously. All acupuncturists were trained 
to apply penetrating sham acupuncture and received a DVD showing de-
tailed information on how to perform the penetrating sham acupuncture. 
Patients of all three groups are allowed to take ≤2 doses of second-
generation oral antihistamines daily (e.g., 2 × 1 cetirizine dihydrochloride/
day), if required. If the clinical symptom(s) of SAR cannot be sufficiently 
stabilised by the antihistamine treatment, an oral steroid can be used ad-
ditionally. The patients are instructed to precisely document the applied 
rescue medication on a daily basis in a special diary.
Patients will be instructed not to use any of the following medications 
or treatments during the study period in both years: topical cromolyns 
(eye drops and nasal spray), topical antihistamines, topical steroids, leu-
kotriene receptor antagonists, anti-cholinergic agents, a-adrenergic ago-
nists, allergen immunotherapy, nasal ipratropium, decongestants, and any 
form of CAM for SAR.
sions in each of the first 4 weeks, followed by 1 session per week in the 
remaining 4 weeks). Patients in the rescue medication group do not re-
ceive acupuncture treatment for a period of 8 weeks. After 8 weeks, they 
also receive the acupuncture treatment described below (waiting list 
 design). In all three groups moxibustion is not allowed.
Acupuncture treatment in the ACUSAR study is semi-standardised 
(table 1): All patients have to be treated at 4 obligatory basic acupuncture 
points: LI 4, LI 11, LI 20 bilaterally, and Ex-HN 3 (Yintang). Further-
more, at least 3 out of 8 facultative basic acupuncture points have to be 
selected according to the principles of traditional Chinese medicine 
(TCM). In addition, patients have to be treated at ≥3 local and/or distant 
acupuncture points. Acupuncturists may use additional points including 
ear acupuncture points. The number and name of all acupuncture points 
used in each session must be documented. A traditional Chinese syn-
drome diagnosis is mandatory and the diagnosis must be documented. 
Needle length and diameter are not predefined but have to be docu-
mented. An irradiating needling sensation (‘de qi’) should be achieved, if 
possible. Needles should be stimulated manually at least once in each 
session. 
Number, duration, and frequency of the sessions in the penetrating 
sham acupuncture group are the same as in the acupuncture group. Par-
Category of points Points Selection
Basic acupuncture points 
(obligatory)
L.I. 4
L.I. 11
L.I. 20
EX-HN 3 Yintang
bilateral (except Yintang),  
altogether 7 points
Basic acupuncture points 
(facultative)
EX-HN 8 BITONG
GB 20
LIV 3
LU 7
ST 36
SP 6
SJ 17
BL 13
uni- or bilateral, ≥3 points
Additional local acupuncture points 
(facultative) 
BL 2
GB 1, 14
EX-HN 5 TAIYANG
SI 18 
SJ 23
ST 2
further points
≥3 points (local and 
distant additional points)  
uni- or bilateral
Additional distant acupuncture points
(facultative) 
LU 1, 5
Ma 44
GB 41, 34, 37
LIV 2
LIV 5
KID 3, 7
BL 12, 20, 23, 26, 40
SP 9
REN 6, 17, 22, 20
SJ 5, 6
further points
Additional ear acupuncture 
(facultative)
Allergy point
Shenmen point
Thymus point
ACTH point 
further points
Table 1. Acupuncture points used in the 
ACUSAR study 
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patients’ constitution, (2) global assessment of change in week 8 by the 
patient measured by the questionnaire on overall treatment effect at 
week 8 after randomisation (0 = worsening, 1 = no change, 2 = slight to 
moderate improvement, 3 = good to excellent improvement); (3) level of 
cost-effectiveness as a result of health economic analyses from a society’s 
perspective, and (4) the number of side-effects and serious and non-seri-
ous adverse events.
In order to test the effectiveness of blinding, patients in the acupunc-
ture and sham acupuncture groups fill in a questionnaire after the 3rd ac-
upuncture session in order to assess the credibility of the respective treat-
ment methods [25]. At the end of the study, patients in these two groups 
are asked whether they believe that they have received acupuncture fol-
lowing the principles of Chinese medicine or the other type of acupunc-
ture. For each session, physicians are asked to report whether side-effects 
or adverse or serious adverse events effects occurred. In addition, the 
 patients are asked to report side-effects in the abovementioned question-
naires (see fig. 1). Drop-outs, withdrawals, and the respective reasons are 
documented.
Data Monitoring and Safety Board
The Data Monitoring and Safety Board (DMSB) ensures the safety of the 
trial participants, the credibility of the study, and the validity and integrity 
of the data. Early in the trial, the DMSB reviews focus on safety, quality 
of conduct, and trial integrity. Interim data reports are submitted every 
other month during the pollen season. Each month during the recruit-
ment phase in the 2 study years, the DSMB receive a report of side- effects 
and any serious adverse events. The DMSB consists of 3 experts inde-
pendent of the study team: a statistician, an expert for research in CAM, 
and an acupuncturist.
Statistical Analysis
The primary outcome measures are the RQLQ and the RMS between 
weeks 6 and 8.
Analyses will be performed for 2 populations: (1) an intention-to-treat 
(ITT) population with all patients randomised and treated with at least 
1 acupuncture session; for the primary analysis, missing values will be re-
placed by multiple imputations, and (2) a per-protocol population includ-
ing only patients with no major protocol deviations. First, all available 
data will be analysed descriptively. Results will be summarised as means, 
standard deviations, and 95%-confidence intervals (CIs) for continuous 
data; medians, quartiles, and ranges for rank data; and percentages for 
discrete data. 
Rescue medication use and quality of life are linked in a complicated 
manner: a higher amount of rescue medication may or may not improve 
quality of life independent of the direct acupuncture effects; on the 
other hand, a reduced quality of life may induce a more intensive use of 
In order to minimise bias from patients’ expectations, patients are in-
formed in the same way as in the in the ART trials [15–18]: ‘In this study, 
different types of acupuncture will be compared. One type is similar to 
the acupuncture treatment used in China. The other type does not follow 
these principles, but has also been associated with positive outcomes in 
clinical studies.’
Outcome Measurement
For the evaluation of the main and secondary outcome measures, patients 
are requested to fill in a questionnaire including the Rhinitis Quality of 
Life Questionnaire (RQLQ) and the symptom scores (global and sub-
scores) before randomisation and at the end of weeks 7, 8, and 16 in the 
1st year and at the beginning of the birch pollen season as well as at the 
end of week 8 in the following year (fig. 2). In addition, patients are re-
quested to fill in diaries including the Rescue Medication Score (RMS) in 
the first 8 weeks and in the weeks 14–16 in the 1st year and in the weeks 
1–2 and 6–8 in the 2nd year.
Main outcome measures in the ACUSAR study are average means of 
the RQLQ overall score and the RMS between weeks 6 and 8 in the 1st 
year, adjusted for baseline values.
The RQLQ is a well-established and validated questionnaire created 
by Juniper et al. [19, 20] and has been used in several clinical studies in 
conventional medicine and also in complementary medicine e.g., in acu-
puncture [9, 12] as a primary or secondary outcome measure. The RQLQ 
consists of an overall score and 7 sub-scores including limitations of ac-
tivities, sleep problems, non-hay fever symptoms, practical problems, 
nasal symptoms, eye symptoms, and emotions. Rescue medication usage 
will be scored daily using the RMS [21] on a 4-point scale as follows: no 
rhinitis medication (0 points); oral antihistamines – 1 × cetirizine dihydro-
chloride 10 mg/day or equivalent (1 point); oral antihistamines – 2 × ceti-
rizine dihydrochloride 10 mg/day (= 20 mg) or equivalent (2 points); any 
form of systemic steroids or other drug for SAR (3 points). 
Secondary outcome measures include the RQLQ score at week 16 in 
the 1st year, and at the end of week 7 and 8 in the 2nd year; the RMS in 
week 1 and between weeks 15 and 16 in the 1st year and between weeks 6 
and 8 during the pollen season in the 2nd year; responders to study inter-
vention are defined as patients with a change in RQLQ score of ≥0.5 be-
tween the baseline RQLQ score and the mean of the RQLQ scores from 
weeks 6 to 8; a Visual Analogue Scale (VAS, 0–100 mm) SAR overall 
symptom severity and the VAS nasal, eye, pharyngeal, and common 
symptoms weekly between baseline and week 8, at week 17 and 18 in the 
1st year, and at weeks 1 and 2, and weeks 6 and 8 in the 2nd year and the 
two summary scales (physical and mental health) of the health-related 
quality of life SF-36 [22, 23]. 
Further secondary outcome parameters are: (1) the ‘Havelhöher Kon-
stitutionsfragebogen’ (T-HKF, Version 2.4) questionnaire [24] to assess 
Name of sham 
acupuncture points 
Areas Selection
Deltoideus In the middle of the insertion line of M. deltoideus (L.I. 14) and 
Acromion (between L.I. and SJ meridian) 
5 out of 7 proposed  
points should be needled  
bilaterally (in total 10 
points)
Upper arm In the mid line between the acupuncture points LU 3 and L.I.14 
Upper leg I 6 cun above the upper edge of the patella (between the spleen 
and stomach meridian)
Upper leg II 5 cun above the upper edge of the patella (between the spleen 
and stomach meridian)
Upper leg III 4 cun above the upper edge of the patella (between the spleen 
and stomach meridian)
Back I 5 cun laterally of the spine of thoracal vertebrum 8
Back II 5 cun laterally of the spine of lumbar vertebrum 1
One cun is defined according to the rules of TCM as the width of the interphalangeal joint of the patient’s thumb.
Table 2. Penetrating 
sham acupuncture 
points used in the 
ACUSAR study
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easy to investigate in this disease. Therefore, we choose as in-
clusion criteria SAR testing positive to grass and birch pollen. 
In Germany, the birch pollen season usually lasts from early 
March to mid May and the grass pollen season from late April 
to mid August resulting in a SAR symptom phase of about 
5 months for each patient annually. However, depending on 
the weather influence and the geographical region, the pollen 
flow is different in strength even in the birch and grass pollen 
season. We cannot control for each patient’s SAR symptoms 
individually but we think that the randomisation process will 
balance the patients according to the different pollen flight 
and SAR symptoms in the three groups. 
As the trial will be performed in a large number of private 
practices without special diagnostic equipment, the inclusion 
and exclusion criteria must be pragmatic. However, the diag-
nosis will have to be defined once by an AR specialist using a 
skin-prick test and/or RAST before study entry. The inclusion 
and exclusion criteria of the study are in accordance with 
those proposed by the Consensus Statement in Allergic Rhin-
itis [1]. The main inclusion criteria (allergy history of >2 years, 
positive prick test to grass and birch pollen, severity of symp-
toms), have been applied in other clinical studies evaluating 
the efficacy of conventional treatment [26, 27] as well as in 
our earlier acupuncture trial [9]. Our study is designed to en-
sure that patient characteristics, and thus also the results of 
this study, will be comparable to previous trials.
Acupuncture practiced according to the principles of Chi-
nese medicine is an individualised therapy [28]. In the 
ACUSAR study, we use a semi-standardised treatment proto-
col, similar to a number of other studies in the past, including 
the 4 ART studies [15–18]. In all patients, we require that a 
number of pre-defined ‘basic points’ be used obligatory and 
facultative. In addition, physicians are allowed to add further 
points based, for example, on an individualised syndrome 
 diagnosis made according to TCM diagnostic methods, or on 
clinical experience. As in the ART trials [15–18], the pre- 
defined ‘basic points’ were selected in a consensus process 
with experienced acupuncture experts while taking the princi-
ples of TCM into account. The main reason for choosing a 
semi-standardised treatment was to foster transparency and a 
certain degree of reproducibility without losing individualisa-
tion. As moxibustion is commonly not used to treat SAR, the 
decision to exclude this treatment which is associated with ac-
upuncture was unproblematic. Many acupuncture studies 
published so far have been criticised for unclear or insufficient 
quality of acupuncture [29]. As in the ART trials [15–18], we 
have used explicit and rigid criteria to ensure that the physi-
cians in the study have a high level of education and practical 
experience. Nevertheless, it must be pointed out that the edu-
cation of German acupuncturists, also in this trial, varies con-
siderably. All trial acupuncturists are physicians who have 
completed their primary training (>80% have ≥350 h of train-
ing) in acupuncture in Germany and have spent little or no 
time training in China.
rescue medication. Thus, it is not sufficient to prove superiority in one 
of the two endpoints if non-inferiority cannot be proven for the other 
endpoint. Correspondingly, for each of the two two-group comparisons, 
non-inferiority has to be proven first for both of the primary outcome 
parameters before superiority in at least one of them is worthwhile to be 
studied. In more detail, for confirmatory testing, an analysis of covari-
ance of the primary outcome measure will be performed in the ITT 
group (1) on the RQLQ between weeks 6 and 8, adjusting for the 
RQLQ score at baseline, and (2) on the RMS between weeks 6 and 8, 
adjusting for the RMS score at baseline. For primary analysis, the test 
procedure will be hierarchical (1-sided tests, a = 0.025): (1) In a first 
step, acupuncture will be compared to penetrating sham acupuncture 
group using a test of non-inferiority with respect to RQLQ. The non-in-
feriority test is significant if the left-sided ANCOVA-based 97.5% CI of 
the between-group difference lies completely above the non-inferiority 
margin of –0.5. (2) In the case of significance in step 1, in a 2nd step, 
acu puncture will be compared to the penetrating sham acupuncture 
group using a test of non-inferiority with respect to RMS. The non-infe-
riority test is significant if the left-sided ANCOVA-based 97.5% CI of 
the between-group difference lies completely above the non-inferiority 
margin of –1.5, chosen proportionally to the non-inferiority limit of the 
RQLQ. (3) In the case of significance in step 2, in a 3rd step, acupunc-
ture will be compared to the sham acupuncture group with a test of 
 superiority with respect to the RQLQ or the RMS. For this purpose, 
2 left-sided ANCOVA-based 98.75% CIs of the between-group differ-
ence in RQLQ and RMS will be calculated and compared to zero. The 
test of superiority is significant if at least one of the two CIs lies com-
pletely above zero. Steps 4, 5, and 6 will be analogous to steps 1, 2, and 
3, but with the rescue medication group instead of the sham acupunc-
ture group. We will perform exploratory analyses for all secondary out-
comes as well as for the comparison of sham acupuncture group with the 
rescue medication group.
For the power calculation, we used the RQLQ data from our previous 
trial on the effectiveness of acupuncture [12]. As no previous data on 
RMS are available, the power calculation was performed only for the two 
hypotheses relating to the RQLQ. However, we assume that our sample 
size will be sufficient, as we expect that the effect sizes shown by acupunc-
ture for the RMS are similar to those shown for the RQLQ. Based on the 
assumption of a non-inferiority limit of 0.5 (= limit of clinical difference; 
see [20] in a 1-sided test (significance level a = 0.025), a power of 80%, 
and a common standard deviation of 1.1 (data from previous trial [12]), 
we used nQuery Advisor® 4.0 to determine a sample size of 164 in the ac-
upuncture group, 82 in the rescue medication control, and 82 in the pen-
etrating sham acupuncture group using a 2:1:1 allocation ratio. Assuming 
a drop-out rate of approximately 20%, we will require a sample size of 
200 in the acupuncture group, 100 in the rescue treatment control, and 
100 in the penetrating sham acupuncture group.
Discussion
To our knowledge, the ACUSAR study is the first clinical 
study to investigate the efficacy of an acupuncture treatment 
for SAR compared to both a penetrating sham acupuncture 
treatment and a standard treatment in a multi-centre 3-armed 
clinical trial. Compared to previous studies of acupuncture in 
the treatment of SAR including a sham acupuncture group, 
the ACUSAR study has a much larger number of participat-
ing acupuncturists, a more rigorous methodology and will in-
clude significantly more patients. 
Because of the discontinuous appearance of symptoms in 
patients with SAR, the effectiveness of acupuncture is not 
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our first two trials on the efficacy of acupuncture in AR [9, 
12]. Therefore, we will be able to compare the results of this 
trial with those of the earlier ones. The documentation and 
analyses of the rescue medication is common in allergy trials 
[36, 37]. However, it would be desirable to take into consider-
ation more objective endpoints in acupuncture research. 
Therefore, we implemented two smaller experimental trials in 
two sub-groups of ACUSAR patients to study changes in im-
munology parameters (ACUSAR EXP) and vegetative func-
tions (AUTO ACUSAR) triggered by acupuncture.
In conclusion, the ACUSAR study is one of the largest and 
most rigorous studies of acupuncture including a sham control 
group conducted in SAR thus far. This study will have an im-
pact on the decision of whether acupuncture should be con-
sidered as a therapeutic option in the treatment of SAR. 
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A major issue in the planning phase of the ACUSAR study 
was the choice of a sham control group. The sponsor of this 
trial, the German research foundation, has explicitly requested 
that research be conducted on acupuncture compared with 
‘placebo,’ or ‘sham’ acupuncture. However, the concepts of 
placebo and its specific, and unspecific effects in relation to 
complex physical interventions such as acupuncture are un-
clear (details see [30]). Various different forms of sham and 
placebo acupuncture were used in the past [31]. Both penetrat-
ing sham acupuncture and the placebo acupuncture with the 
sham acupuncture needle [32] touch the skin and therefore 
evoke activity of cutaneous afferent nerves [33]. We are aware 
that penetrating sham acupuncture is not a valid placebo inter-
vention [33]. But as all other sham control concepts fail to rep-
resent a valid placebo as well, we use – as in the ART trials – 
penetrating sham acupuncture as ‘sham control group’. 
For standard treatment we use oral second-generation an-
tihistamines and – in the case of not sufficiently treated SAR 
symptoms – in addition oral steroids. However, the guideline 
treatment also includes topical oral antihistamines or steroids 
as primary or second-line treatment [1]. The reason to choose 
oral antihistamines in the rescue medication treatment was 
that oral antihistamines are still the most widely used SAR 
treatment and, in addition, the RMS can be calculated more 
easily.
In this study, we apply a range of outcome measures com-
monly used in AR research. Both primary outcome measures, 
the RQLQ overall score and the RMS are well established 
and of clear clinical relevance: The RQLQ is a well-validated 
questionnaire [19, 20] and has been used in several high- 
quality studies as a primary outcome parameter [26, 34, 35]. A 
further advantage is that we have already used the RQLQ in 
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